



Actinogen
Medical

Alzheimer's Treatment Needs a New Approach – Xanamem™

BIO International Convention – June 2018

Disclaimer

This presentation has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Actinogen, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Actinogen and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Actinogen is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Actinogen securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Actinogen its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Actinogen does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

This presentation contains certain forward looking statements that are based on the Company’s management’s beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Actinogen to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which Actinogen will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Actinogen and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

Actinogen Medical (ASX:ACW)

- Developing Xanamem for the treatment of Alzheimer's disease (AD) and cortisol-associated cognitive impairment
- Xanamem, a novel differentiated mechanism of action: prevents the production of excess brain cortisol
- Persistently raised cortisol in the brain is associated with the development and progression of AD
- First-in-class, brain penetrant, orally active, inhibitor of 11 β HSD1 enzyme, reducing conversion of cortisone to cortisol
- Experienced board and management; expert clinical and scientific advisory boards

Largest holders

Pending completion of the Placement of 300,000,000 shares (Tranche 1 and 2) and the Share Purchase Plan (SPP)*

- **Biotechnology Value Fund, L.P.**
- **Platinum Investment Management Limited**
- **Edinburgh Technology Fund Limited**
- **Australian Ethical Investment**
- JK Nominees
- Sunset Capital Management
- Warambi Sarl
- BNP Paribas Nominees



* Announced 23 May 2018

Interim analysis – DSMB recommendation to continue trial without modification*



- Interim Analysis undertaken by independent Data Safety Monitoring Board (DSMB)
- Safety and efficacy data reviewed
- Conducted on data from first 50 evaluable XanADu trial patients. Additional 37 patients' safety data included in the analysis
- No treatment related serious adverse events
- Recommendation affirms the positive benefit-risk safety profile of Xanamem 10mg daily
- Supports progression of study as planned
- Underpins further development in other indications

XanADu

* Announced 23 May 2018

Substantial Institutional investment in Actinogen*

Recognises potential and endorses strategy

- Positive interim analysis catalyses significant \$15M investment through Placement
- Leading investors enter register:
 - USA specialist biotech investor **Biotechnology Value Fund L.P.**
 - Australian institutions **Platinum Investments Management** and **Australian Ethical Investment**
- Strong endorsement - Placement price represents an 13.4% premium to the 5-day VWAP
- BVF cornerstones Placement to become the largest shareholder with a 19.9% holding
- Funding to advance Company's development plan through additional Xanamem studies. Focus on enhancing the data-set for Xanamem, adding substantial value to ongoing partnering discussions



* Announced 23 May 2018

New Xanamem studies – funded through May '18 capital raising

Enhancing value, broadening scope, strengthening data-set

- New funding to advance Company's development plan
- Focus on enhancing the data-set for Xanamem, broadening scope of use and adding substantial value to asset
 - Target engagement and safety studies – to help define optimum dose
 - Additional standard toxicology studies required by regulators (positioning Xanamem for Phase III development)
 - New indications




Cortisol inhibition improves cognition – key factor in 2014 acquisition

Two 2004 pilot studies concluded that inhibiting cortisol production in the brain with carbenoxolone improves cognitive function in healthy elderly men & type 2 diabetics – established Edinburgh Uni cortisol hypothesis

VERBAL FLUENCY – Study 1*


P=0.006



* Study 1 = 10 healthy subjects Age 55-75 (Mean Age = 65.5 ± 5.5) receiving 100mg carbenoxolone 3 times daily compared to placebo for 4 weeks, in a double-blind randomised crossover study.

VERBAL MEMORY – Study 2**

P=0.005



**Study 2 = 12 type 2 diabetics (m=9; f=3) Age 52-70 (Mean Age = 60 ± 4.9) receiving 100mg carbenoxolone 3 times daily compared to placebo for 6 weeks, in a double-blind randomised crossover study.

Significant improvement in verbal fluency and verbal memory after only 4 and 6 weeks treatment


11β-Hydroxysteroid dehydrogenase inhibition improves cognition function in healthy elderly men and type 2 diabetics
Sandeep et al., 2004 PNAS (vol. 101, no. 17) 6734-6739

Robust animal data with new candidate - key factor in 2014 acquisition

Symptomatic and disease modifying effects in mouse models – AUD \$25 million invested pre-acquisition


COGNITION: treatment 28 days

P=0.004



AMYLOID CLEARANCE: treatment 28 days

P=0.01



Significant improvement in cognition after only 28 days treatment, continuing out to 41 weeks

UE2316 in Tg2576 rodent model of Alzheimer's disease.
Sooy, et al., 2015. Endocrinology 156 (12) 4592-4603



Xanamem

Xanamem

- A novel, first in class, potent, orally bioavailable, brain-penetrant, 11 β HSD1 inhibitor¹
- Differentiated mechanism of action: blocking cortisol production in the brain
- Symptomatic and disease modifying effects *in vivo*¹
- Well-tolerated – dosed >100 patients/subjects: acceptable clinical safety, toxicity and PK/PD profile¹
- Effective human brain concentrations demonstrated¹
- XanADu – phase II clinical study underway, dosing subjects with mild AD dementia in USA, UK, AU
- Planning ongoing for additional clinical indications
- Composition of matter IP coverage $\geq$ 2031, patents granted in all major markets
- XanADu Alzheimer's trial fully funded following completion of ~A\$5.3 million capital raise in November 2017
- A range of additional studies adequately funded following completion of ~\$17 million capital raising in May 2018



1. Webster *et al.*, 2017, British J Pharmacol 174:396-408

Cortisol: a validated biomarker and target for AD

Cortisol and Alzheimer's


- Recent independent studies support the association between cortisol and AD development and progression¹⁻⁵
- Cognitive impairment in patients with neuroendocrine dysfunction⁶⁻⁹
- Compelling evidence provided by the Australian Imaging, Biomarker & Lifestyle Study of Ageing (AIBL) study (2017)⁵
 - Subjects with higher plasma cortisol at much greater risk of developing AD
 - Accelerated effect of A β + on decline in global cognition, episodic memory and attention

Xanmem

- Data presented at four major international medical congresses in 2016 – AAIC Toronto; CTAD San Diego; ICE Beijing; MMC Lisbon
- Pre-clinical and Phase I data published¹⁰⁻¹¹



MEAN CSF CORTISOL LEVELS




[1] Geerlings et al., 2015, Neurology 85: 1-8; [2] Lehallier et al., 2016, JAMA Neurology 73(2), 203-212; [3] Popp et al., 2015, Neurobiol. Aging 36:601–607; [4] Ennis et al., 2017, Neurology 88(4):371-378; [5] Pietrzak et al., 2017, Biol Psychiatry: Cognitive Neuroscience and Neuroimaging, 2:45-52; [6] Lupien et al., 2009, Nat Rev Neurosci 10:434–445; [7] Starkman et al., 1999, Biol Psychiatry 46: 1595–1602; [8] Lupien et al., 1998, Nat Neurosci 1:69–73; [9] MacLulich et al., 2005, Psychoneuroendocrinology 30:505–515; [10] Sooy et al., 2015, Endocrinology 156(12):4592-4603; [11] Webster et al., 2017, British J Pharmacol 174:396-408.

Cortisol, cognitive decline and AD: a growing body of literature


Recent relevant reviews:

- Cortisol: Mediator of association between Alzheimer's disease and diabetes mellitus? (Notarianni, 2017, *Psychoneuroendocrinology*)
- Unified theory of Alzheimer's disease (UTAD): implications for prevention and curative therapy. (Nehls 2016, *J Mol Psychiatry*)
- Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases? (Du and Pang, 2015; *Front Psychiatry*)
- The impact of stress and glucocorticoids on memory. (Tatomir et al. 2014; *Clujul Med.*)
- Contribution of glucocorticoids and glucocorticoid receptors to the regulation of neurodegenerative processes. (Vyas and Maatouk, 2013; *CNS Neurol Disord Drug Targets*)
- Stress-induced cytokines and neuronal dysfunction in Alzheimer's disease. (Ricci et al., 2012; *J. Alzheimer's Dis.*)
- Local amplification of glucocorticoids in the aging brain and impaired spatial memory (Yau and Seckl, 2012; *Front. Aging Neuroscience*)


PUBMED:"CORTISOL AND COGNITION"



PUBMED: "CORTISOL AND ALZHEIMER'S"



Xanamem pipeline of indications, back-up compounds*



* Back-up compounds to Xanamem, licenced from Edinburgh University



XanADu – Phase II Trial

XanADu – Xanamem in Alzheimer's disease



Phase II double blind, randomised, placebo-controlled study to assess the efficacy and safety of Xanamem in participants with mild Alzheimer's disease*

- 103 patients enrolled (60% of total study cohort) and more than 68 patients already completed study**
- On track for last patient enrolled in Q4 2018 and top line results in Q2 2019
- Interim Analysis on first 50 evaluable patients - DSMB recommends continuing XanADu without modification



Xanamem treatment course
12 weeks



174
Mild Alzheimer's patients



Xanamem 10mg daily
for 12 weeks vs placebo



Trial conducted at 20 sites in
AUS, USA and UK

Primary and secondary endpoints are standard and experimental cognitive outcome measures used in Alzheimer's research: ADASCog14, ADCOMS, CDR-SOB, MMSE, RAVLT, NTB-ED

* Registered on Clinicaltrials.gov: NCT02727699

** As at 31 May 2018



Investment potential

Commercially experienced, globally recognised

Board of Directors



Dr. Geoff Brooke
Chairman



Dr. Bill Ketelbey
CEO & MD



Dr. Jason Loveridge
Non-Executive Director



Dr. George Morstyn
Non-Executive Director

Xanamem Clinical Advisory Board




Prof. Craig Ritchie
Chair



Prof. Colin Masters




Prof. Jeffrey Cummings



Peer comparison

What big pharma companies are paying for acquisition of drug developers in the Alzheimer's space





Xanamem™ - summary

Summary



A huge market with a significant unmet medical need

Xanamem

- Differentiated, with a novel mechanism of action
- Small molecule - oral
- High quality development plan and regulatory review
- Solid IP out to at least 2031
- Potential utility in other neurological indications

XanADu

- Fully funded to completion of XanADu
- Additional studies funded with May 2018 capital raise
- Interim Analysis – continue study without modification
- On track for last patient enrolled before end 2018
- 103 patients enrolled (60% of total); 68 already completed



Substantial independent support for cortisol/Alzheimer's hypothesis



Highly experienced Board



Growing interest in Xanamem from pharma partners



A compelling investment opportunity

Dr. Bill Ketelbey

CEO & Managing Director

☎ Main: +61 2 8964 7401

Email: bill.ketelbey@actinogen.com.au

www.actinogen.com.au




Actinogen
Medical



Appendix

Xanamem journey of discovery



Recent comparable deals

Assets with Alzheimer's disease as the lead indication or key indication

Licensee/acquirer	Licensor/acquired	Year	Candidate(s)	Phase	Deal Value (US\$M)	Upfront (US\$M)
Takeda	Denali	2018	ATV platform, three programs	Pre-clinical	<u>~\$1,000</u>	\$150
AbbVie	Voyager	2017	AAV anti-tau antibodies	Pre-clinical	<u>\$1,109</u>	\$69
Biogen	BMS	2017	BMS-986168	Ph 1	<u>\$710</u>	\$300
Allergan	Heptares	2016	Three M1/M4 agonists	Ph I	<u>\$3,340</u>	\$125
Janssen	AC immune	2015	ACI-35	Ph Ib	<u>\$509</u>	Undisclosed
Merck	Bionomics	2014	BNC-375	pre-clinical	<u>\$526</u>	\$20
Eli Lilly	AstraZeneca	2014	AZD3293	Ph I	<u>\$500</u>	\$50
Iperian	BMS	2014	IPN007	pre-clinical	<u>\$725</u>	\$175
Otsuka	Lundbeck	2013	Idalopirdine	Ph II	<u>\$825</u>	\$150
Janssen	Orion	2013	ORM-12741	Ph IIa	<u>Undisclosed</u>	\$31